FDA Times ZIIHERA Patent Clock, Generics Wait in Line
Published Date: 4/3/2026
Notice
Summary
The FDA has set the official review period for the drug ZIIHERA, which helps the company extend its patent protection. This affects the patent holder and anyone interested in the drug’s approval timeline. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting how long the patent lasts and when generics can enter the market.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA sets ZIIHERA review period length
The FDA determined the regulatory review period for ZIIHERA is 3,038 days (2,801 days in the testing phase and 237 days in the approval phase). This determination establishes the maximum potential length of a patent extension; the applicant (Zymeworks BC Inc.) is seeking 1,346 days of patent term extension from the USPTO.
FDA records differ from applicant's claimed dates
FDA verified the investigational new drug exemption effective date as July 29, 2016, but FDA records show the biologics license application (BLA 761416) was submitted on March 29, 2024 (the applicant claimed December 15, 2023). FDA records show approval on November 20, 2024 (the applicant claimed November 21, 2024). These specific dates were used to derive the regulatory review period.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in